MX2020011341A - Una composicion para el tratamiento de una o mas enfermedades relacionadas con los estrogenos. - Google Patents
Una composicion para el tratamiento de una o mas enfermedades relacionadas con los estrogenos.Info
- Publication number
- MX2020011341A MX2020011341A MX2020011341A MX2020011341A MX2020011341A MX 2020011341 A MX2020011341 A MX 2020011341A MX 2020011341 A MX2020011341 A MX 2020011341A MX 2020011341 A MX2020011341 A MX 2020011341A MX 2020011341 A MX2020011341 A MX 2020011341A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- treating
- related diseases
- estrogen
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere al tratamiento de una o más enfermedades relacionadas con los estrógenos mientras se previene o se reduce la probabilidad de desarrollar efectos secundarios relacionados con la deficiencia de estrógenos, en donde dicha composición comprende administrar una cantidad terapéuticamente eficaz de un antagonista de GnRH a un paciente que necesita dicho tratamiento, y en donde dicha cantidad de antagonista de GnRH es suficiente para proporcionar un nivel medio de estradiol sérico endógeno de entre aproximadamente 20 pg/ml y 60 pg/ml, preferiblemente entre 30 pg/ml y 50 pg/ml, en dicho paciente en un período de tratamiento de por lo menos cuatro semanas, sin depender de la terapia de "adición". Dicha composición y método es simple, eficaz y, en consecuencia, aumentará tanto la aceptación del paciente como el cumplimiento de la terapia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18169419.1A EP3560555A1 (en) | 2018-04-26 | 2018-04-26 | A composition for treating one or more estrogen related diseases |
| PCT/EP2019/060570 WO2019207026A1 (en) | 2018-04-26 | 2019-04-25 | A composition for treating one or more estrogen related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011341A true MX2020011341A (es) | 2020-11-24 |
Family
ID=62067442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011341A MX2020011341A (es) | 2018-04-26 | 2019-04-25 | Una composicion para el tratamiento de una o mas enfermedades relacionadas con los estrogenos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11446351B2 (es) |
| EP (2) | EP3560555A1 (es) |
| JP (1) | JP2021522227A (es) |
| KR (1) | KR20210003868A (es) |
| CN (1) | CN112041028A (es) |
| AU (1) | AU2019258514A1 (es) |
| BR (1) | BR112020021565A2 (es) |
| CA (1) | CA3097267A1 (es) |
| IL (1) | IL277876A (es) |
| MA (1) | MA52359A (es) |
| MX (1) | MX2020011341A (es) |
| WO (1) | WO2019207026A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3590525A1 (en) * | 2018-07-05 | 2020-01-08 | Antev Limited | Teverelix-tfa composition |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681817A (en) * | 1994-02-04 | 1997-10-28 | The Medical College Of Hampton Roads | Treatment of ovarian estrogen dependent conditions |
| EP0769956B1 (en) * | 1994-07-22 | 2000-03-15 | The Medical College Of Hampton Roads | USE OF A GnRH ANTAGONIST FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF GONADAL-STEROID CONDITIONS |
| US5658884A (en) * | 1994-07-22 | 1997-08-19 | The Medical College Of Hampton Roads | Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens |
| EP1214086A2 (en) * | 1999-09-23 | 2002-06-19 | Zentaris AG | Method for the therapeutic management of endometriosis and fallopian tube obstruction |
| US7005418B1 (en) * | 1999-09-23 | 2006-02-28 | Zentaris Gmbh | Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction |
| JP2004529207A (ja) * | 2001-04-30 | 2004-09-24 | ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｌｈｒｈアンタゴニストの中間の用量での痴呆及び神経変性疾患の治療 |
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| US7098305B2 (en) | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
| WO2008071984A1 (en) * | 2006-12-13 | 2008-06-19 | Ardana Bioscience Limited | Administration of the gonadotropin-releasing hormone antagonist teverelix |
-
2018
- 2018-04-26 EP EP18169419.1A patent/EP3560555A1/en not_active Withdrawn
-
2019
- 2019-04-25 MA MA052359A patent/MA52359A/fr unknown
- 2019-04-25 JP JP2020558886A patent/JP2021522227A/ja active Pending
- 2019-04-25 KR KR1020207033860A patent/KR20210003868A/ko unknown
- 2019-04-25 WO PCT/EP2019/060570 patent/WO2019207026A1/en active Application Filing
- 2019-04-25 AU AU2019258514A patent/AU2019258514A1/en not_active Abandoned
- 2019-04-25 CA CA3097267A patent/CA3097267A1/en not_active Abandoned
- 2019-04-25 CN CN201980028492.6A patent/CN112041028A/zh active Pending
- 2019-04-25 US US17/050,430 patent/US11446351B2/en active Active
- 2019-04-25 EP EP19727289.1A patent/EP3784346A1/en active Pending
- 2019-04-25 BR BR112020021565-1A patent/BR112020021565A2/pt not_active IP Right Cessation
- 2019-04-25 MX MX2020011341A patent/MX2020011341A/es unknown
-
2020
- 2020-10-08 IL IL277876A patent/IL277876A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3097267A1 (en) | 2019-10-31 |
| MA52359A (fr) | 2021-03-03 |
| JP2021522227A (ja) | 2021-08-30 |
| AU2019258514A1 (en) | 2020-10-22 |
| US20210052692A1 (en) | 2021-02-25 |
| EP3784346A1 (en) | 2021-03-03 |
| IL277876A (en) | 2020-11-30 |
| WO2019207026A1 (en) | 2019-10-31 |
| KR20210003868A (ko) | 2021-01-12 |
| EP3560555A1 (en) | 2019-10-30 |
| US11446351B2 (en) | 2022-09-20 |
| BR112020021565A2 (pt) | 2021-01-19 |
| CN112041028A (zh) | 2020-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gersema et al. | Use of corticosteroids in oral surgery | |
| Pedersen | Decadronphosphate® in the relief of complaints after third molar surgery: A double-blind, controlled trial with bilateral oral surgery | |
| Craig et al. | When is prophylaxis for hereditary angioedema necessary? | |
| NZ592039A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| NZ591362A (en) | Multiple-variable dose regimen for treating tnfa-related disorders | |
| WO2002005791A3 (en) | Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor | |
| PT100323A (pt) | Dispositivo para a reducao das sensacoes durante a administracao iontoforetica de um agente terapeutico | |
| CY1105199T1 (el) | Θepαπευτικες συνθεσεις για αντιμετωπιση της υπepεκκρισης βλεννας | |
| NO20030955D0 (no) | Fremgangsmåte for behandling av ereksjon feilfunksjon og ökning av libido hos menn | |
| HUP0301813A2 (hu) | Nem-orális androgén szteroidok | |
| SG146666A1 (en) | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders | |
| MX336710B (es) | Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades. | |
| ATE367816T1 (de) | Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten | |
| NZ536633A (en) | Percutaneous delivery of testosterone via a hydroalcoholic gel as a method of increasing testosterone and related steroid concentrations in women | |
| WO2020186132A8 (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| BR112022010806A2 (pt) | Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama | |
| Tsukanov et al. | Orthostatic-loading-induced transient venous refluxes (day orthostatic loading test), and remedial effect of micronized purified flavonoid fraction in patients with telangiectasia and reticular vein | |
| ATE531366T1 (de) | Zusammensetzungen und verfahren zur behandlung, verminderung, verbesserung oder linderung von erkrankungen des hinteren augensegments | |
| MX2020011341A (es) | Una composicion para el tratamiento de una o mas enfermedades relacionadas con los estrogenos. | |
| Elkamshoushi et al. | Oral tranexamic acid, hydroquinone 4% and low‐fluence 1064 nm Q‐switched Nd: YAG laser for mixed melasma: clinical and dermoscopic evaluation | |
| DE69519933T2 (de) | Prostaglandinanaloga zur oralen oder vaginalen verabreichung in der routinebehandlung des dritten stadiums der geburtswehen | |
| de Villiers | Bone health and menopause: Osteoporosis prevention and treatment | |
| BR0308584A (pt) | Composição farmacêutica androgênica e método para tratamento de depressão | |
| BR0012408A (pt) | Métodos para induzir ou aumentar a migração celular, para reduzir ou inibir a migração celular, para induzir ou aumentar a cura de ferimento em um paciente, e para regular a expressão de pelo menos um gene de uma célula, e, uso de um agonista de fator de tecido | |
| SE9902597D0 (sv) | New use |